Antigens.---One preparation of the random terpolymer of L-glutamic acid6°-L-alaninea°-Ltyrosine 1° (GAT) with an average molecular weight of 55,000 was purchased from Pilot Chemicals Div., New England Nuclear Corporation, Boston, Mass. A second preparation of GAT, average molecular weight of 32,000, was purchased from Miles Laboratory, Kankakee, Ill. The two GAT preparations were identical in their immunological properties. Stock solutions of 10 mg/ml were prepared in normal saline containing 1% Na2COa at pH 9.0-9.5. The stock solution of GAT was sterilized by filtration and diluted in Hanks' balanced salt solution (HBSS) for addition to spleen cell cultures. A sterile solution of GAT was complexed to a sterile solution of methylated bovine serum albumin (a gift from Dr. Paul Maurer, Jefferson Medical College) according to his technique (6) . Sheep red blood cells (SRBC) were prepared as previously described (8) for addition to spleen cell cultures or for use in the hemolytic plaque assay.
Mouse Anti-GA T Serum.--Sera were obtained from several mice undergoing a secondary response to GAT, pooled, decomplemented by heat at 56°C for 30 min and absorbed three times in the cold with packed SRBC equivalent to 20% of the volume of serum.
Rabbit Anti-GA T Serum.--This serum, kindly donated by Dr. E. Dunham, was obtained from rabbits 7 days after the second immunization with 1 mg GAT in Freund's complete adjuvant. The anti-GAT activity of this serum was determined by a modified Farr assay (3) and bound 75 #g GAT/ml of serum. This serum was also heat inactivated and absgrbed three times in the cold with packed SRBC equal to 20% of the serum volume.
Goat Antimouse #-Chain Serum.--This serum was a gift from Dr. R. Asofsky, National
Institutes of Health. The specificity of the serum and its effects on the development of immunoglobulin (Ig) class-specific anfi-SRBC responses in vitro have been described in detail previously (9) . This serum was added to spleen cell cultures with antigen at culture initiation as 50 #1 of a 1 : 25 dilution of serum.
Rabbit Antimouse Immunogloblulin Sera.--A polyvalent rabbit antimouse IgG s~rum was routinely used to develop indirect PFC. Rabbit antisera specific for mouse "Y1, ")'2a+b, or "YA Ig classes were used in some experiments to develop class-specific indirect PFC. The specificity of these sera has been previously described in detail (8) . These sera were also a gift from Dr. R. Asofsky.
Immunization of Mice.--Mice were immunized with 10 #g GAT or with GAT-MBSA c~n-taining 10 /zg GAT as a suspension in a mixture of magnesium-aluminum hydroxide gel (Maalox, Wm. H. Rorer, Inc., Fort Washington, Pa.) and pertussis vaccine (Eli Lilly and Co., Indianapolis, Ind.) as previously described (3).
Preparation of GAT Coupled SRBC (GAT-SRBC
).--GAT was coupled to SRBC with chromium chloride (CrC13) (J. T. Baker Chemical Co., Phillipsburg, N. J.) by a modification of the method described by Gold and Fudenberg (10) . The optimal ratio of reactants was determined empirically and is described below. SRBC in Alsever's solution (Colorado Serum Co., Denver, Cvl.) were washed three times by centrifugation and resuspended to 10~ in 0.85% NaC1. CrCla was pulverized and dissolved in 0.85% NaC1 (10 mg/ml) immediately before use. At room temperaure, 1.0 ml of 10% SRBC was mixed with 1.0 ml of the GAT solution (10 mg/ml) in a 50 ml centrifuge tube. 1 ml of the freshly prepared solution of CrCls was pipetted into the mixture of GAT and SRBC. The reaction was allowed to proceed for 1-2 min without stirring and was terminated by adding 45 ml of PBS (0.15M NaC] containing 0.001 M phos-phates, pH 7.2). The coupled cells were washed three times by centrifugation with 50 ml PBS and resuspended in medium L-15 (Microbiological Associates, Bethesda, Md.) to 1% for the 51Cr release assay or to 7.5% for the hemolytic plaque assay.
Antibody-Me.dialed Lysis of GA T-SRBC.--The susceptibility of GAT-SRBC indicator cells
to lysis by anti-GAT antibodies and complement (C) was determined. SRBC and GAT-SRBC were labeled with SlCr by reacting 0.1 mCi Na251CrO4 (The Radiochemical Centre, Amersham, England) with 3 X 108 cells in 1.0 ml of medium L-IS for 30 min at 37°C. The cells were washed three times by centrifugation with 50 ml volumes of L-15 containing 10% fetal calf serum. The 51Cr-labeled cells, 0.1 ml of 3 X l0 T cell/ml, were mixed with 0.1 ml of diluted mouse anti-GAT serum and 0.1 ml of guinea pig serum (BBL Div. of BioQuest, Cockeysville, Md.) as a source of C. After incubation at 37°C for 1 h, the amount of 51Cr released into the supernate was determined using a Packard gamma scintillation counter (Packard Instrument Co., Inc., Downers Grove, Ill.). The percent of 51Cr released by the antiserum was determined using a distilled water-lysed control as 100% release and subtracting the amount of 51Cr released by C alone from the total released by antiserum and C by the following relationship:
(S1Cr released by antiserum -b C) --(SXCr released by C) %S1Cr release = (siC r released by H20 lysis) --(SaCr released by C) X 100.
Reproducibility of Coupling GA T to SRBC.--GAT-SRBC prepared on several different days with GAT were tested with one mouse anti-GAT serum and C in the 51Cr release assay. Comparison of the 50% end points in Fig. 1 , shows a difference of less than one twofold dilution indicating that this method of preparation GAT-SRBC provided indicatgr ceils which measure anti-GAT activityin serum in a consistent manner. This anti-GAT serum released no 5XCr when tested on uncoupled SRBC. When GAT-SRBC prepared with GAT from Miles Laboratory or from Pilot Chemicals Co. were compared in a 51Cr release assay there was no significant difference in 50% end points with the standard mouse anti-GAT serum. Furthermore, when soluble GAT was added to a 1~0 dilution of this serum, 100% of the 51Cr released by the anti-GAT serum was inhibited with GAT at concentrations of 0.1/zg or greater. These concentrations of GAT had no effect on the release of 51Cr from labeled SRBC by an anti-SRBC serum. GAT- SRBC indicator cells prepared by this method can also be used in microtiter systems to detect hemagglutinating activity in sera of mice immunized with GAT or GAT-MBSA in vivo.
Spleen Cell Cultures.--Suspensions of single spleen cells containing 10 X 10 6 nucleated cells/ ml of culture medium (MEM) were incubated according t? the method of Mishell and Dutton (7) with modifications previously described in detail (8) . Experimental groups were incubated as duplicate cultures and each experiment contained cultures unstimulated, stimulated with 10 7 SRBC, and appropriate concentrations of GAT or GAT-MBSA.
Hemolytic Plaque Assay.--PFC in spleen cell cultures or in the spleens of mice immunized in vivo were enumerated by a modification of the Jerne hemolytic plaque technique described in detail previously (8) . Suspensions of spleen ceils were washed three times before assay to remove any soluble GAT. IgM PFC were enumerated after incubation of indicator red cells, SRBC or GAT-SRBC, and spleen cells in semi-solid agarose using guinea pig serum as a source of C. IgG PFC were developed with polyvalent rabbit antimouse IgG serum and C in assay preparations containing sufficient goat antimouse #-chain antibody to inhibit the development of all IgM PFC (8) . Each cell suspension was examined in agarose mixtures c~ntaining SRBC and in mixtures containing GAT-SRBC. The specificity of anti-GAT PFC was verified by adding 10 #g of soluble GAT to the assay mix tures to inhbit development of anti-GAT plaques. This concentration of soluble GAT reproducibly inhibited all anti-GAT PFC, while causing no, nonspecific, inhibition of development of anti-SRBC PFC. GAT-specific PFC were calculated by subtracting the number of PFC uninhibited by soluble GAT on GAT-SRBC from the number of PFC detected on GAT-SRBC in the absence of soluble GAT. Data are expressed as GATspecific PFC/spleen for in vivo experiments and as GAT-specific PFC/culture for in vitro experiments.
RESULTS

Primary GAT-Specific Responses In
Vivo.--In preliminary experiments, the first GAT-specific PFC in C57B1/6 mice were detected 4 days after immunization with GAT and the maximum number was obtained by day 7. Fig. 2 illustrates the primary GAT-specific PFC responses in spleens of SJL (nonresponders), C57B1/6 (responders), and the F: hybrid of C57B1/6 X SJL (responders) mice 7 days after immunization in vivo with 10/~g of GAT as GAT-MBSA in Maalox-pertussis. No IgM PFC specific for GAT were found in the spleens of any of these mice at any time from 4 to 15 days after immunization. The C57B1/6 and the F1 mice developed GAT-specific IgG PFC responses when immunized with GAT, whereas the SJL mice did not. All three strains developed GAT-specific IgG PFC responses to GAT-MBSA.
Development of _Primary and Secondary GAT-Specific PFC Responses In
Vitro.--Spleen cells from normal C57B1/6, SJL, and the F1 (C57B1/6 X SJL) mice were stimulated in vitro with either 107 SRBC, GAT-MBSA (5/zg GAT/ culture), or various concentrations of soluble GAT. After 5 days, the time of the maximum response to SRBC, the cultures were examined for anti-SRBC PFC and anti-GAT PFC. The results in Fig. 3 show that cultures of C57B1/6
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Iĩi i ĩi ĩ!~!~i I liiiiiiiiiiii!i and F1 spleen cells developed GAT-specific IgG PFC responses to several doses of soluble GAT. Although 10 ~g GAT stimulated the maximum response in cultures of C57B1/6 spleen cells in this experiment, many other experiments have shown that 1 #g and 10 #g GAT stimulated comparable PFC responses; concentrations of soluble GAT higher than 10 #g always elicited a lower PFC response. Cultures of SJL spleen cells developed no GAT-specific IgG response at any concentration of GAT. All three strains developed GAT-specific IgG PFC responses to GAT-MBSA, and, although not shown, all three strains developed IgM and IgG anti-SRBC PFC responses. Again, no IgM PFC specific for GAT were detected in any of these cultures.
Kinetics of Appearance of GAT-Specific IgG PFC.--Cultures of spleen cells
from normal C57B1/6 and SJL mice, and C57B1/6 mice immunized 6 wk earlier with 10/~g GAT in Maalox-pertussis were examined at various times after initiation for the development of PFC responses to SRBC and GAT.
At the time this experiment was done, 1 #g GAT elicited the maximal GATspecific PFC responses in cultures of spleen cells from normal C57B1/6 mice. The GAT-specific IgG PFC response in cultures of C57B1/6 spleen cells (Fig.  4) reached a peak after 5 days incubation with 1/~g of GAT; no GAT-specific IgG PFC response was detected in cultures incubated with 0.1/~g GAT. Spleen cells from C57B1/6 mice primed with GAT developed GAT-specific IgG PFC responses to both 0.1 ]~g and 1.0/~g GAT (Fig. 5) , which also reached peaks after 5 days incubation. The GAT-specific PFC responses by spleen cells from GAT-primed mice were always approximately two times greater in magnitude than the responses in cultures of spleen cells from normal C57B1/6 mice. No IgM PFC specific for GAT were detected at any time in cultures of normal or primed spleen cells from C57B1/6 mice. Spleen cells from normal SJL mice (Fig. 6 ) did not develop GAT-specific IgM or IgG PFC responses to either dose of soluble GAT at any time, however, they did develop an anti-SRBC IgM and IgG PFC response reaching a peak after 4 days incubation with SRBC. In subsequent in vitro studies, the PFC responses were assayed after 5 days incubation. 
Specificity of Stimulation by GAT In
Vitro.--The experiment shown in Fig. 7 demonstrates that the primary GAT-specific PFC response in cultures of C57B1/6 spleen cells was the result of specific antigenic stimulation by GAT. Rabbit anti-GAT serum, extensively absorbed with SRBC in the cold, was added to cultures stimulated with SRBC or GAT at culture initiation. 50 pl of a 1~25 dilution of this serum had no effect on the anti SRBC IgG PFC response, but, completely inhibited the GAT-specific IgG PFC response stimulated by 10/~g GAT. 50 #i of a 1/625 dilution of anti-GAT serum had no effect on either the anti-SRBC or GAT-specific PFC responses. classes of anti-SRBC PFC were also determined. The results in Table I show that anti-SRBC PFC in cultures of spleen cells from C57B1/6 and SJL mice are approximately 50% 71,30% ")'2, and 12-20% ")'A • The GAT-specific PFC in cultures of spleen cells from normal SJL mice stimulated in vitro with GAT-MBSA, and from normal C57B1/6 mice stimulated in vitro with GAT or GAT-MBSA were 80-100% "Yl, 0-3 % ")'2, and 6-18 % "YA • Whereas, primary GAT-specific PFC responses by C57B1/6 and SJL spleen cells were predominately of the "y~ class, with few or no "g~ PFC, the secondary GAT-specific responses by SJL spleen cells stimulated with GAT-MBSA and C57B1/6 spleen cells stimulated with GAT contained significant numbers of GAT-specific PFC of the ~ Ig class. The total number of PFC developed by the class-specific antisera does not equal the number of PFC developed by the polyvalent rabbit anti-IgG serum, nor is it expected to, since the polyvalent serum is not a pool of the class-specific sera. [I Spleen cells from mice primed with 10/zg GAT as GAT-MBSA in Maalox-pertussis 6 wk previously.
Immunoglobulin Class of GA T-Specific PFC.--The
Effect of Antimouse #-Chain Serum on the Development o/GAT-Specific PFC
Responses In Vitro.--We have never detected IgM PFC specific for GAT in these experiments. This is unusual since IgM antibodies are usually found in responses to antigens which also stimulate synthesis of IgG antibodies. Furthermore, as previously reported, both primary IgM and IgG PFC responses to SRBC in vitro can be inhibited by incubating spleen cells in the presence of goat antibody to mouse/z-chain. This suppression by anti-/z-chain serum was shown to be mediated through the precursors of antibody-producing cells presumably by combining with the IgM surface receptors for antigen and thus preventing effective stimulation by. antigen (9) . If the GAT-specific IgG PFC response by spleen cells in vitro could also be inhibited with anti-/~-chain serum, this would be presumptive evidence that precursors of GAT-specific PFC had IgM receptors for antigen on their cell surface. 50 #1 of a 1/65 or 1/~0 0 dilution of goat anti-/z-chain serum was added to cultures of C57B1/6 spleen cells stimulated with SRBC, GAT, or GAT-MBSA and to cultures of SJL spleen cells stimulated with SRBC and GAT-MBSA at culture initiation. The results (Table II) demonstrate that GAT-specific IgG PFC responses in both strains were inhibited 90 % or more by incubation with the 1/~5 dilution of anti-/z-chain serum; the 1~0 0 dilution suppressed the responses by 60-100%.
Responses of Various Strains of Mice to GA T and GA T-MBSA In
Vitro.--To rule out any possibility that the failure of spleen cells from SJL mice to respond to soluble GAT in vitro is a peculiarity of this particular strain of mice rather than being attributable to the H-2 ~ genotype, we tested two congenic It-28 nonresponder strains of mice in our system. We chose the B10.S strain, a congenic resistant strain of the H-28 histocompatibility genotype on a C57B1/10 back- GAT-MBSA GAT-SRBC 0 0 1 / 100 GAT-MB SA GAT-SRB C 0 0 * Anti-/z serum was added to 1.0 ml cultures as 50/zl of the indicated dilution.
ground. This strain has the same H-2 type as the SJL, and is otherwise essentially identical with the C57B1/6 responder mice used in these studies. We also tested the A.SW strain of mice, a congenic resistant strain also of the H-2 ~ histocompatibility type, but on an A strain background. A/J mice were included in this study since they possess the same non-H-2 genotype as the A.SW, but they have the H-2 ~ histocompatibility type and are thus responders to GAT. Spleen cells from all five strains were incubated with SRBC, or 10/zg GAT, or 5/zg GAT as GAT-MBSA. All strains developed IgM and IgG anti-SRBC PFC responses. The GAT-specific IgG PFC responses to GAT and GAT-MBSA are shown in Fig. 8 . No IgM PFC specific for GAT were detected in cultures of any of these mice. Spleen cells from all five strains of mice developed GATspecific IgG PFC responses to GAT-MBSA; but only the C57B1/6 and A/J strains developed responses to soluble GAT. None of the three strains of mice bearing the H-28 genotype developed a response to soluble GAT in culture, proving that this failure is not a peculiarity of the SJL strain of mice. Furthermore, the linkage of responsiveness to GAT and t/-2 histocompatibility type previously reported using in vivo serological techniques (3) has now been demonstrated for PFC responses using an in vitro system.
DISCUSSION
These experiments demonstrate that mouse antibody to the random terpolymer GAT can be detected by complement-dependent lysis of SRBC which have GAT complexed to their surfaces. This hemolysis can be quantitated by The maximal GAT-specific PFC responses were detected 5 days after culture initiation; the optimal concentration of soluble GAT varied between 1 to 10 #g GAT/ culture. In the primary response in vitro, all detected GAT-specific PFC elicited by GAT or GAT-MBSA have been indirect PFC predominantly of the 71 class with few or no PFC of the 7~ class. The majority of GAT-specific PFC in the secondary response in vitro are also of the 71 class, but a significant number of GAT-specific PFC of 73 class are also detected. No direct, IgM, GAT-specific PFC have been detected in vivo or in vitro. There are three possible explanations for this observation: (a) IgM antibodies specific for GAT are produced but GAT-SRBC are not lysed by these antibodies in the presence of complement; (b) some IgM GAT-specific PFC are present but are too few in number or too transient in their secretory phase to be detected; or (c) no IgM antibodies to GAT are synthesized. There is no direct evidence to support any one of these possibilities; however, some circumstantial evidence suggests that the first explanation is unlikely. That is, we have found that equal numbers of IgM anti-SRBC PFC can be detected using SRBC or GAT-SRBC as indicator cells. Therefore, the coupling of GAT to the SRBC has not rendered the red cells insensitive to lysis by IgM antibody and complement. Unless mouse IgM anti-GAT antibody is unable to fix complement, the first explanation is an unlikely possibility. Although the finding that development of GAT-specific IgG PFC responses can be inhibited by incubation of the spleen cell cultures with goat antimouse t~-chain serum tells us that anti-GAT PFC precursors have IgM receptors for antigen on their cell surfaces, it does not tell us whether or not IgM antibodies specific for GAT are ever synthesized. At this time, we cannot choose between explanations 2 and 3. The lack of detectable IgM antibody specific for GAT is nonetheless significant. GAT elicits an all-or-none response in mice and thus differs from some other synthetic polypeptide antigens the response to which is under the control of Ir genes. These data therefore show that genetic control of GAT-specific PFC responses in vitro correlates precisely with previous data obtained by measuring serum antibody responses to GAT. The in vitro system described in this study will be used as a model to study the cellular events regulated by the H-2-1inked Ir genes. The cellular requirements for the development of antibody responses to GAT and GAT-MBSA in vitro are the subject of the accompanying paper (13) . Subsequent papers in this series will deal with the cellular defect(s) in non-responder mice which are responsible for their failure to develop antibody responses to soluble GAT both in vivo and in vitro.
SUMMARY
In vivo, the antibody response in mice to the random terpolymer L-glutamic acid6°-L-alanine3°-L-tyrosine 1° (GAT) is controlled by a histocompatibilitylinked immune response gene(s). We have studied antibody responses by spleen cells from responder and nonresponder mice to GAT and GAT complexed to methylated bovine serum albumin (GAT-MBSA) in vitro. Cells producing antibodies specific for GAT were enumerated in a modified Jerne plaque assay using GAT coupled to sheep erythrocytes as indicator cells. Soluble GAT stimulated development of IgG GAT-specific plaque-forming cell (PFC) responses in cultures of spleen cells from responder mice, C57B1/6 (H-2b), F1 (C57)< SJL) (H-2b/8), and A/J (H-2a). Soluble GAT did not stimulate development of GATspecific PFC responses in cultures of spleen cells from nonresponder mice, SJL (H-2*), B10.S (H-28), and A.SW (H-2"). GAT-MBSA stimulated development of IgG GAT-specific PFC responses in cultures of spleen cells from both responder and nonresponder strains of mice. These data correlate precisely with data obtained by measuring the in vivo responses of responder and nonresponder strains of mice to GAT and GAT-MBSA by serological techniques. Therefore, this in vitro system can effectively be used as a model to study the cellular events regulated by histocompatibility-linked immune response genes.
